Abstract:Background The prevalence of inflammatory bowel disease (IBD) has been on the rise in developing countries. However, the mechanism of interaction between gut microbiota and immunity, especially how probiotics regulate the imbalance of mucosal immunity in IBD, remains unclear. Hence, this study aims to explore the role of Clostridium butyricum (C. butyricum) in M2 macrophage-mediated intestinal barrier injury repairation regarding the mechanism of efferocytosis. Methods C. butyricum was treated in DSS-induced colitis mice to observe the gut barrier and the macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (A) The flow chart of the experiment). The efferocytosis-related gene expression in terms of mucosal healing was explored in colitis mice with or without clodronate liposome treatment. RNA-sequencing was used to study the mechanism of C. butyricum on macrophage efferocytosis. Results We found that C. butyricum relieved intestinal inflammation and intestinal barrier injury in colitis mice (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (B,C) The wight loss and histological images of mice). M2 macrophages and the efferocytosis-related genes were upregulated after C. butyricum treatment (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (D-I) The frequency and efferocytosis-related genes expression of macrophage). Macrophage deletion induced by clodronate liposomes prevented the role of C. butyricum on the intestinal barrier and macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (J-M) The effect of C. butyricum after macrophage clearance). RNA-sequencing revealed differentially expressed genes upregulated and downregulated (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (A) The numbers of differentially expressed genes after C. butyricum treatment). KEGG enrichment results suggested that the PPAR pathway were significantly enriched and the expression of PPAR pathway-related genes was identified (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (B,C) The result of enrichment analysis and differentially expressed genes that enriched in PPAR pathway). C. butyricum upregulated the expression of PPARδ and PPARγ, not PPARα (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (D-F) The relative expression of genes). Furthermore, PPARγ inhibitor GW9662 instead of PPARδ inhibitor GSK3787 could prevent the role of C. butyricum in inflammation suppression and macrophage efferocytosis promotion (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (G,H) The weight loss and colon length of mice). Conclusions Our findings demonstrated that C. butyricum attenuated intestinal inflammation and barrier injury by promoting M2 macrophage polarization and efferocytosis, which is partly mediated by PPARγ activation.

Butyrate Induces Intestinal Epithelial Cell to Express Thrombospondin 1 and Suppress Intestinal Mucosal Inflammation

Thrombospondin 1 Modulates Monocyte Properties to Suppress Intestinal Mucosal Inflammation

Butyrate Attenuates Intestinal Inflammation in Crohn’s Disease by Suppressing Pyroptosis of Intestinal Epithelial Cells Via the Cgsa-Sting-nlrp3 Axis

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Insulin-Like Growth Factor-1 Endues Monocytes with Immune Suppressive Ability to Inhibit Inflammation in the Intestine

Effects and Mechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier in DSS-Induced Colitis

Butyrate alleviates murine colitis by promoting the expansion of myeloid-derived suppressor cells

Clostridium Butyricum Alleviates Intestinal Low-Grade Inflammation In Tnbs-Induced Irritable Bowel Syndrome In Mice By Regulating Functional Status Of Lamina Propria Dendritic Cells

Clostridium Butyricum Activates Tlr2-Mediated Myd88-Independent Signaling Pathway in Ht-29 Cells

An Important Role of Interleukin-10 in Counteracting Excessive Immune Response in HT-29 Cells Exposed to Clostridium Butyricum

Commensal A4 Bacteria Inhibit Intestinal Th2-Cell Responses Through Induction Of Dendritic Cell Tgf-Beta Production

Immunomodulatory effects of Clostridium butyricum on human enterocyte-like HT-29 cells

The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate

IDDF2024-ABS-0252 Clostridium Butyricum Attenuates Intestinal Barrier Injury by Promoting PPARγ-mediated Efferocytosis in Macrophages

Butyrate Functions in Concert with Myeloid-Derived Suppressor Cells Recruited by CCR9 to Alleviate DSS-induced Murine Colitis.

Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Butyrate Inhibits Interleukin-17 and Generates Tregs to Ameliorate Colorectal Colitis in Rats

Roseburia intestinalis and Its Metabolite Butyrate Inhibit Colitis and Upregulate TLR5 through the SP3 Signaling Pathway

Microbial metabolite butyrate modulates granzyme B in tolerogenic IL-10 producing Th1 cells to regulate intestinal inflammation

Thrombospondin-1 aggravates colonic mucosal inflammatory injuries via promoting the differentiation of CD11c+ macrophages with lysosomal activity limited in colitis